1. Phylogeny  
   FN3KRP (UniProt Q9HA64), also termed fructosamine‐3‐kinase‐related protein or protein‐psicosamine 3‐kinase, is a member of the protein kinase–like (PKL) superfamily that participates in cellular deglycation pathways. Comparative sequence analysis indicates that FN3KRP shares approximately 65% amino acid similarity with its paralog fructosamine‐3‐kinase (FN3K) in mammals, a similarity that underscores its evolution via gene duplication from an ancestral FN3K‐like gene. Orthologous sequences of FN3KRP have been identified across vertebrate species including mammals and birds, with evolutionary studies suggesting that the gene duplication event occurred after the divergence of fish from the vertebrate lineage (beeraka2021thetamingof pages 12-14, conner2005somecluesas pages 1-3, fortpied2005plantribulosamineerythrulosamine3kinase pages 1-2). Moreover, tissue distribution and evolutionary analyses have demonstrated conservation of the genomic context and housekeeping promoter architecture for FN3KRP, reinforcing its role as a fundamentally expressed maintenance enzyme during evolution (delplanque2004tissuedistributionand pages 1-2).
2. Reaction Catalyzed  
   FN3KRP catalyzes an ATP‐dependent phosphorylation reaction in which it transfers the γ‐phosphate from ATP to a specific hydroxyl group located on protein‐bound ketosamine substrates. More precisely, the enzyme phosphorylates the 3‐hydroxyl group of ketosamine adducts—specifically targeting ribuloselysine and psicoselysine residues that form on proteins as a consequence of nonenzymatic glycation reactions. The overall chemical reaction can be represented as:  
     ATP + [glycated‐protein]–(ketosamine) → ADP + [glycated‐protein]–(ketosamine‐3‐phosphate) + H⁺  
   The phosphorylation generates ribuloselysine‐3‐phosphate or psicoselysine‐3‐phosphate, intermediates that are inherently unstable and decompose under physiological conditions, thereby facilitating the removal of the glycation adduct and the regeneration of the unmodified lysine residue (beeraka2021thetamingof pages 14-15, fortpied2005plantribulosamineerythrulosamine3kinase pages 1-2, szwergold2011thephysiologicalsubstrates pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of FN3KRP is strictly ATP‐dependent and necessitates the presence of divalent metal ions. Mg²⁺ is the primary cofactor required for effective kinase activity. During the phosphorylation reaction, Mg²⁺ forms a complex with ATP to correctly position the nucleotide for phosphate transfer within the active site of the enzyme. This metal ion dependency has been consistently observed in experimental kinase assays and purification protocols, where buffers supplemented with MgCl₂ are essential for maintaining enzymatic activity (delplanque2004tissuedistributionand pages 2-3, yonesu2011purificationandidentification pages 3-4, szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2).
4. Substrate Specificity  
   FN3KRP displays a substrate specificity that is distinct from its paralog FN3K. While FN3K phosphorylates protein‐bound fructosamines, FN3KRP is unable to utilize fructoselysine as a substrate. Instead, FN3KRP preferentially acts on ketosamine substrates generated by non‐enzymatic glycation reactions, specifically phosphorylating ribuloselysine and psicoselysine residues on glycated proteins. The enzyme exhibits a stereospecific preference for these substrates, targeting the ketosamine adducts that arise from D‐orientation sugars during glycation (beeraka2021thetamingof pages 14-15, fortpied2005plantribulosamineerythrulosamine3kinase pages 1-2, szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2).
5. Structure  
   FN3KRP conforms to a classical protein kinase–like fold that is characteristic of the PKL enzyme superfamily. Its overall structural organization features a central kinase domain divided into two lobes: an N‐terminal lobe responsible for binding ATP and positioning the phosphate donor, and a larger C‐terminal lobe that primarily facilitates substrate recognition and binding. Conserved catalytic motifs are present in the structure, with an invariant lysine residue (analogous to the Lys41 found in FN3K) essential for coordinating ATP binding, as well as an aspartate-rich motif (DxxxxN) within the catalytic loop that contributes to catalytic activity (beeraka2021thetamingof pages 12-14, conner2005somecluesas pages 1-3).  
   Detailed structural models based on crystallographic studies of FN3K homologs, as well as AlphaFold predictive models, have revealed that FN3KRP retains the key structural features of a bilobal kinase domain, including a glycine-rich P-loop at the N-terminus that is critical for nucleotide binding. Notably, this P-loop in FN3KRP contains a conserved redox-sensitive cysteine residue that is implicated in the formation of reversible disulfide bonds. These disulfide bonds have been demonstrated in related kinases to trigger changes in the oligomeric state, such as the formation of redox-active dimers, which in turn modulate the enzyme’s activity (shrestha2020aredoxactiveswitch pages 1-1, shrestha2020aredoxactiveswitch pages 5-5). Such a redox-active switch is a unique structural feature that sets FN3KRP apart from many other serine/threonine kinases that do not exhibit redox-regulated oligomerization.
6. Regulation  
   Regulatory control of FN3KRP occurs predominantly by mechanisms that are intrinsic to its biochemical properties and post‐translational modifications. The promoter region of FN3KRP is characterized as a housekeeping type, generally lacking TATA and CAAT boxes while containing CpG islands and binding sites for Sp1 transcription factors. This promoter architecture underlies the constitutive expression pattern of FN3KRP observed in various tissues (conner2005somecluesas pages 1-3, delplanque2004tissuedistributionand pages 1-1).  
   At the protein level, FN3KRP is regulated by the redox status of the cell. A conserved cysteine residue located within the P-loop of the kinase domain serves as a redox-sensitive switch. Under oxidizing conditions, this cysteine can form intermolecular disulfide bonds that promote dimerization of the enzyme; the formation of disulfide-linked dimers has been shown to alter the kinase’s catalytic efficiency by affecting nucleotide binding and substrate access. Conversely, reducing conditions—provided by agents such as dithiothreitol (DTT) or physiological reducing agents like glutathione—disrupt these disulfide bonds, favoring a monomeric state that is associated with higher enzymatic activity (shrestha2020aredoxactiveswitch pages 1-1, shrestha2020aredoxactiveswitch pages 5-7, delplanque2004tissuedistributionand pages 2-3).
7. Function  
   FN3KRP functions as a key enzyme in the deglycation repair pathway. Its primary biological role is the phosphorylation of ketosamine groups present on glycated proteins. In particular, FN3KRP catalyzes the phosphorylation of ribuloselysine and psicoselysine residues—glycation adducts that result from non‐enzymatic reactions between proteins and reducing sugars. The phosphate group is transferred from ATP to the ketosamine substrate, resulting in the formation of ribuloselysine‐3‐phosphate or psicoselysine‐3‐phosphate; these phosphorylated products are unstable, decomposing spontaneously to regenerate the free lysine residue on the protein. This catalytic action thus serves as a protein repair mechanism, mitigating the accumulation of glycation products that are implicated in the formation of advanced glycation end products (AGEs) (beeraka2021thetamingof pages 12-14, fortpied2005plantribulosamineerythrulosamine3kinase pages 1-2, szwergold2011thephysiologicalsubstrates pages 1-2).  
   FN3KRP is expressed in a broad range of tissues and cell types, consistent with its classification as a housekeeping enzyme. While its expression levels may be lower than those of FN3K in some tissues, FN3KRP’s ubiquitous presence emphasizes its importance in maintaining protein quality by regulating glycation status—a pathway that is particularly significant under hyperglycemic conditions where non‐enzymatic glycation is augmented (conner2005somecluesas pages 3-8, avemaria2015possibleroleof pages 1-2).
8. Other Comments  
   FN3KRP is emerging as an important component of the cellular maintenance machinery responsible for the repair of damaged proteins arising from non‐enzymatic glycation. Its unique substrate specificity—phosphorylating ribuloselysine and psicoselysine rather than the fructoselysine targets of FN3K—distinguishes its functional role within the deglycation pathway (szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2). In addition, FN3KRP has been investigated in the context of drug metabolism; purification protocols and kinase assays performed in human erythrocytes have demonstrated that the enzyme can phosphorylate pharmacological substrates such as CS-0777, a sphingosine 1-phosphate receptor modulator, thereby linking its biochemical function to potential applications in therapeutic activation and modulation (yonesu2011purificationandidentification pages 3-4).  
   Furthermore, by virtue of its role in protein deglycation, FN3KRP is of considerable interest with respect to metabolic diseases such as diabetes, where an imbalance between glycation and deglycation processes can contribute to the accumulation of AGEs and subsequent tissue damage. Although direct inhibitors specific to FN3KRP have not been as extensively characterized as those for other kinases, its central role in the deglycation network may render it a promising target for future therapeutic strategies aimed at reducing glycation-related cellular damage. Genetic polymorphisms in related deglycation enzymes have been associated with differences in glycation marker levels, underscoring the clinical relevance of these protein repair mechanisms (avemaria2015possibleroleof pages 1-2, szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 3-5).
9. References
10. Beeraka, N., Bovilla, V.R., Doreswamy, S.H., Puttalingaiah, S., Srinivasan, A., & Madhunapantula, S. “The taming of nuclear factor erythroid-2-related factor-2 (NRF2) deglycation by fructosamine-3-kinase (FN3K)-inhibitors—a novel strategy to combat cancers.” Cancers, Jan 2021. URL: https://doi.org/10.3390/cancers13020281, doi:10.3390/cancers13020281. (pages 12-14, 14-15)
11. Conner, J.R., Beisswenger, P.J., & Szwergold, B.S. “Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein.” Annals of the New York Academy of Sciences, Jun 2005. URL: https://doi.org/10.1196/annals.1333.095, doi:10.1196/annals.1333.095. (pages 1-3, 3-8, 8-13)
12. Delplanque, J., Delpierre, G., Opperdoes, F.R., & Van Schaftingen, E. “Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein.” Journal of Biological Chemistry, Nov 2004. URL: https://doi.org/10.1074/jbc.m407678200, doi:10.1074/jbc.m407678200. (pages 1-1, 1-2, 2-3, 3-4, 4-5)
13. Fortpied, J.F., Gemayel, R., Stroobant, V., & Van Schaftingen, E. “Plant ribulosamine/erythrulosamine 3-kinase, a putative protein-repair enzyme.” Biochemical Journal, Jun 2005. URL: https://doi.org/10.1042/bj20041976, doi:10.1042/bj20041976. (pages 1-2, 5-6)
14. Garg, A., On, K.F., Xiao, Y., Elkayam, E., Cifani, P., David, Y., & Joshua-Tor, L. “The molecular basis of human FN3K mediated phosphorylation of glycated substrates.” Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. (pages 8-10, 8-8, 1-2, 2-3, 6-8)
15. Shrestha, S., Katiyar, S., Sanz-Rodriguez, C.E., Kemppinen, N.R., Kim, H.W., Kadirvelraj, R., Panagos, C., Keyhaninejad, N., Colonna, M., Chopra, P., Byrne, D.P., Boons, G.J., van der Knaap, E., Eyers, P.A., Edison, A.S., & Wood, Z.A. “A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily.” Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. (pages 1-1, 5-5, 5-7, 7-8, 9-10)
16. Szwergold, B.S., Manevich, Y., Payne, L., & Loomes, K. “Fructosamine-3-kinase-related protein phosphorylates glucitolamines on the C-4 hydroxyl: novel substrate specificity of an enigmatic enzyme.” Biochemical and Biophysical Research Communications, Oct 2007. URL: https://doi.org/10.1016/j.bbrc.2007.07.127, doi:10.1016/j.bbrc.2007.07.127. (pages 1-2, 2-3, 3-5, 6-6)
17. Szwergold, B.S., Bunker, R.D., & Loomes, K.M. “The physiological substrates of fructosamine-3-kinase-related-protein (FN3KRp) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products).” Medical Hypotheses, Nov 2011. URL: https://doi.org/10.1016/j.mehy.2011.07.027, doi:10.1016/j.mehy.2011.07.027. (pages 1-2)
18. Avemaria, F., Carrera, P., Lapolla, A., Sartore, G., Chilelli, N.C., Paleari, R., Ambrosi, A., Ferrari, M., & Mosca, A. “Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients.” Clinical Chemistry and Laboratory Medicine, Aug 2015. URL: https://doi.org/10.1515/cclm-2015-0207, doi:10.1515/cclm-2015-0207. (pages 1-2)
19. Yonesu, K., Kubota, K., Tamura, M., Inaba, S., Honda, T., Yahara, C., Watanabe, N., Matsuoka, T., & Nara, F. “Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.” Journal of Biological Chemistry, Jul 2011. URL: https://doi.org/10.1074/jbc.m110.217299, doi:10.1074/jbc.m110.217299. (pages 3-4)

References

1. (beeraka2021thetamingof pages 12-14): N. Beeraka, Venugopal R. Bovilla, Shalini H Doreswamy, Sujatha Puttalingaiah, A. Srinivasan, and S. Madhunapantula. The taming of nuclear factor erythroid-2-related factor-2 (nrf2) deglycation by fructosamine-3-kinase (fn3k)-inhibitors-a novel strategy to combat cancers. Cancers, Jan 2021. URL: https://doi.org/10.3390/cancers13020281, doi:10.3390/cancers13020281. This article has 25 citations and is from a peer-reviewed journal.
2. (beeraka2021thetamingof pages 14-15): N. Beeraka, Venugopal R. Bovilla, Shalini H Doreswamy, Sujatha Puttalingaiah, A. Srinivasan, and S. Madhunapantula. The taming of nuclear factor erythroid-2-related factor-2 (nrf2) deglycation by fructosamine-3-kinase (fn3k)-inhibitors-a novel strategy to combat cancers. Cancers, Jan 2021. URL: https://doi.org/10.3390/cancers13020281, doi:10.3390/cancers13020281. This article has 25 citations and is from a peer-reviewed journal.
3. (conner2005somecluesas pages 1-3): JAMES R. CONNER, PAUL J. BEISSWENGER, and BENJAMIN S. SZWERGOLD. Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein. Annals of the New York Academy of Sciences, 1043:824-836, Jun 2005. URL: https://doi.org/10.1196/annals.1333.095, doi:10.1196/annals.1333.095. This article has 50 citations and is from a peer-reviewed journal.
4. (delplanque2004tissuedistributionand pages 2-3): Jérôme Delplanque, Ghislain Delpierre, Fred R. Opperdoes, and Emile Van Schaftingen. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. Journal of Biological Chemistry, 279:46606-46613, Nov 2004. URL: https://doi.org/10.1074/jbc.m407678200, doi:10.1074/jbc.m407678200. This article has 67 citations and is from a domain leading peer-reviewed journal.
5. (fortpied2005plantribulosamineerythrulosamine3kinase pages 1-2): Juliette FORTPIED, Rita GEMAYEL, Vincent STROOBANT, and Emile van SCHAFTINGEN. Plant ribulosamine/erythrulosamine 3-kinase, a putative protein-repair enzyme. Biochemical Journal, 388:795-802, Jun 2005. URL: https://doi.org/10.1042/bj20041976, doi:10.1042/bj20041976. This article has 40 citations and is from a domain leading peer-reviewed journal.
6. (shrestha2020aredoxactiveswitch pages 1-1): Safal Shrestha, Samiksha Katiyar, Carlos E. Sanz-Rodriguez, Nolan R. Kemppinen, Hyun W. Kim, Renuka Kadirvelraj, Charalampos Panagos, Neda Keyhaninejad, Maxwell Colonna, Pradeep Chopra, Dominic P. Byrne, Geert J. Boons, Esther van der Knaap, Patrick A. Eyers, Arthur S. Edison, Zachary A. Wood, and Natarajan Kannan. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. This article has 23 citations and is from a domain leading peer-reviewed journal.
7. (szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 1-2): Benjamin Szwergold, Yefim Manevich, Leo Payne, and Kerry Loomes. Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the c-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Biochemical and biophysical research communications, 361 4:870-5, Oct 2007. URL: https://doi.org/10.1016/j.bbrc.2007.07.127, doi:10.1016/j.bbrc.2007.07.127. This article has 12 citations and is from a peer-reviewed journal.
8. (szwergold2007fructosamine3kinaserelatedproteinphosphorylatesglucitolamines pages 3-5): Benjamin Szwergold, Yefim Manevich, Leo Payne, and Kerry Loomes. Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the c-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Biochemical and biophysical research communications, 361 4:870-5, Oct 2007. URL: https://doi.org/10.1016/j.bbrc.2007.07.127, doi:10.1016/j.bbrc.2007.07.127. This article has 12 citations and is from a peer-reviewed journal.
9. (szwergold2011thephysiologicalsubstrates pages 1-2): Benjamin S. Szwergold, Richard D. Bunker, and Kerry M. Loomes. The physiological substrates of fructosamine-3-kinase-related-protein (fn3krp) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products). Medical Hypotheses, 77:739-744, Nov 2011. URL: https://doi.org/10.1016/j.mehy.2011.07.027, doi:10.1016/j.mehy.2011.07.027. This article has 10 citations and is from a peer-reviewed journal.
10. (avemaria2015possibleroleof pages 1-2): Francesca Avemaria, Paola Carrera, Annunziata Lapolla, Giovanni Sartore, Nino Cristiano Chilelli, Renata Paleari, Alessandro Ambrosi, Maurizio Ferrari, and Andrea Mosca. Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients. Clinical Chemistry and Laboratory Medicine (CCLM), 53:1315-1320, Aug 2015. URL: https://doi.org/10.1515/cclm-2015-0207, doi:10.1515/cclm-2015-0207. This article has 23 citations.
11. (conner2005somecluesas pages 3-8): JAMES R. CONNER, PAUL J. BEISSWENGER, and BENJAMIN S. SZWERGOLD. Some clues as to the regulation, expression, function, and distribution of fructosamine‐3‐kinase and fructosamine‐3‐kinase‐related protein. Annals of the New York Academy of Sciences, 1043:824-836, Jun 2005. URL: https://doi.org/10.1196/annals.1333.095, doi:10.1196/annals.1333.095. This article has 50 citations and is from a peer-reviewed journal.
12. (delplanque2004tissuedistributionand pages 1-1): Jérôme Delplanque, Ghislain Delpierre, Fred R. Opperdoes, and Emile Van Schaftingen. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. Journal of Biological Chemistry, 279:46606-46613, Nov 2004. URL: https://doi.org/10.1074/jbc.m407678200, doi:10.1074/jbc.m407678200. This article has 67 citations and is from a domain leading peer-reviewed journal.
13. (delplanque2004tissuedistributionand pages 1-2): Jérôme Delplanque, Ghislain Delpierre, Fred R. Opperdoes, and Emile Van Schaftingen. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. Journal of Biological Chemistry, 279:46606-46613, Nov 2004. URL: https://doi.org/10.1074/jbc.m407678200, doi:10.1074/jbc.m407678200. This article has 67 citations and is from a domain leading peer-reviewed journal.
14. (shrestha2020aredoxactiveswitch pages 5-5): Safal Shrestha, Samiksha Katiyar, Carlos E. Sanz-Rodriguez, Nolan R. Kemppinen, Hyun W. Kim, Renuka Kadirvelraj, Charalampos Panagos, Neda Keyhaninejad, Maxwell Colonna, Pradeep Chopra, Dominic P. Byrne, Geert J. Boons, Esther van der Knaap, Patrick A. Eyers, Arthur S. Edison, Zachary A. Wood, and Natarajan Kannan. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. This article has 23 citations and is from a domain leading peer-reviewed journal.
15. (shrestha2020aredoxactiveswitch pages 5-7): Safal Shrestha, Samiksha Katiyar, Carlos E. Sanz-Rodriguez, Nolan R. Kemppinen, Hyun W. Kim, Renuka Kadirvelraj, Charalampos Panagos, Neda Keyhaninejad, Maxwell Colonna, Pradeep Chopra, Dominic P. Byrne, Geert J. Boons, Esther van der Knaap, Patrick A. Eyers, Arthur S. Edison, Zachary A. Wood, and Natarajan Kannan. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. This article has 23 citations and is from a domain leading peer-reviewed journal.
16. (yonesu2011purificationandidentification pages 3-4): Kiyoaki Yonesu, Kazuishi Kubota, Masakazu Tamura, Shin-ichi Inaba, Tomohiro Honda, Chizuko Yahara, Nobuaki Watanabe, Tatsuji Matsuoka, and Futoshi Nara. Purification and identification of activating enzymes of cs-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes. Journal of Biological Chemistry, 286:24765-24775, Jul 2011. URL: https://doi.org/10.1074/jbc.m110.217299, doi:10.1074/jbc.m110.217299. This article has 14 citations and is from a domain leading peer-reviewed journal.